NR1H4 and metabolic dysfunction-associated steatotic liver disease: In MASLD patients, alterations in the gut microbiota result in an overall increase in total BA levels, accompanied by a concurrent decrease in the proportion of BAs that act as FXR and TGR5 agonists.